Seattle, WA (Press Release) – Juno Thera­peutics, Inc. (NASDAQ: JUNO), a bio­pharma­ceu­tical com­pany devel­op­ing inno­va­tive cellular immuno­therapies for the treat­ment of cancer, today announced three license agree­ments to ad­vance its pro­gram in multiple myeloma using gamma secretase inhibitors (GSIs) in com­bi­na­tion with BCMA-directed CAR T cells.

Gamma secretase is an enzyme that cleaves a set of transmembrane proteins, in­clud­ing BCMA. Multiple publications have shown that treat­ment with GSIs can in­crease surface ex­pres­sion of BCMA on tumors, particularly multiple myeloma. Increased cell surface BCMA may in­crease potency of a BCMA-directed CAR T ther­apy¹.

“BCMA …